» Test Menu » PML RARA Short and Long form by qRT PCR, Minimal Residual Disease* Client Login | Email | Phone: 1.865.380.9746

PML RARA Short and Long form by qRT PCR, Minimal Residual Disease*

Test Code


Test Synonyms

PML RARA t(15;17) short form, PML RARA t(15;17) long form


Acute promyelocytic leukemia (APL), FAB M3;



Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for PML/RARA t(15;17) long form and PML/RARA t(15;17) short form
*performed by affiliate laboratory

Turnaround Time

5-7 days

Specimen Requirements

5 mL (Min.1 mL) whole blood; 3 mL (Min.1 mL) bone marrow; EDTA only

Specimen Stability
Stable at 2-8°C; Specimen must be received by MPLN within 48 hours of collection.
Stability (collection to initiation of testing): Ambient: 1 hour; Refrigerated: 48 hours
Storage & Handling

Specimens must be received within 48 hours of collection due to lability of RNA.
Ship peripheral blood and bone marrow with cool/refrigerated pack (Do not allow
cool/refrigerated pack to directly contact sample)
Please call before shipping on Friday for weekend delivery.

Causes for Rejection

Specimen >48 hours old; Frozen Specimen; Specimen clotted; Stored or shipped at incorrect temperature; Incorrect anticoagulant; Insufficient specimen volume; Severely hemolyzed specimen

Reference Range

Positive: PML/RARA short or long fusion detected and quantified

Negative: PML/RARA short or long fusion not detected (0.002% PML/RARA)


Utilized for the determination of baseline PML/RARA fusion gene transcript levels and monitoring of same for molecular evidence of minimal residual disease (MRD) or molecular remission in patients with AML-M3 (APL) after induction and consolidation therapy.

  1. Gabert J et al. (2003).  Standardization and quality control studies of real time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual detection in leukemia-A Europe against cancer program. Leukemia. 17:2318-2357.
  2. Reiter et al. (2004). Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematologica.  112:55
  3. Sanz MA. (2006). Treatment of acute promyelocytic leukemia. Hematology. 147-155.